192 related articles for article (PubMed ID: 36641455)
1. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
2. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract][Full Text] [Related]
3. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
[TBL] [Abstract][Full Text] [Related]
4. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
5. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F; Maffioli M; Cervantes F; Vannucchi AM; Morra E; Barbui T; Caramazza D; Pieri L; Rumi E; Gisslinger H; Knoops L; Kiladjian JJ; Mora B; Hollaender N; Pascutto C; Harrison C; Cazzola M
Blood; 2014 Mar; 123(12):1833-5. PubMed ID: 24443442
[TBL] [Abstract][Full Text] [Related]
6. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
[TBL] [Abstract][Full Text] [Related]
9. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
Gerds AT; Yu J; Shah A; Xi A; Kumar S; Scherber R; Parasuraman S
J Med Econ; 2023; 26(1):843-849. PubMed ID: 37294103
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
14. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
[No Abstract] [Full Text] [Related]
16. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
17. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
18. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan KM; Elmeshhadany AY; Shabila NP
Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
